Ipswich Investment Management Co. Inc. Cuts Stake in Moderna, Inc. (NASDAQ:MRNA)

Ipswich Investment Management Co. Inc. decreased its stake in Moderna, Inc. (NASDAQ:MRNA) by 20.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,795 shares of the company’s stock after selling 1,235 shares during the period. Ipswich Investment Management Co. Inc.’s holdings in Moderna were worth $320,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of MRNA. Cedar Wealth Management LLC lifted its holdings in shares of Moderna by 45.0% during the 1st quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock valued at $31,000 after buying an additional 90 shares during the last quarter. Commerzbank Aktiengesellschaft FI lifted its stake in Moderna by 1.7% in the second quarter. Commerzbank Aktiengesellschaft FI now owns 5,550 shares of the company’s stock valued at $660,000 after acquiring an additional 93 shares during the last quarter. CVA Family Office LLC grew its position in Moderna by 21.6% in the second quarter. CVA Family Office LLC now owns 541 shares of the company’s stock worth $64,000 after acquiring an additional 96 shares in the last quarter. Claro Advisors LLC increased its stake in shares of Moderna by 2.0% during the 2nd quarter. Claro Advisors LLC now owns 5,546 shares of the company’s stock worth $659,000 after purchasing an additional 108 shares during the last quarter. Finally, McAdam LLC raised its holdings in shares of Moderna by 1.1% during the 2nd quarter. McAdam LLC now owns 11,075 shares of the company’s stock valued at $1,315,000 after purchasing an additional 117 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on MRNA. Royal Bank of Canada reiterated a “sector perform” rating and issued a $75.00 price objective on shares of Moderna in a report on Thursday, September 19th. TD Cowen lowered their price objective on Moderna from $70.00 to $60.00 and set a “hold” rating on the stock in a report on Friday, September 13th. Wolfe Research assumed coverage on Moderna in a report on Friday. They issued an “underperform” rating and a $40.00 target price for the company. UBS Group lowered their price target on Moderna from $140.00 to $108.00 and set a “buy” rating on the stock in a report on Thursday, October 24th. Finally, Hsbc Global Res upgraded shares of Moderna from a “moderate sell” rating to a “hold” rating in a research note on Wednesday, August 28th. Three analysts have rated the stock with a sell rating, fourteen have given a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $90.22.

Insider Buying and Selling at Moderna

In other news, CFO James M. Mock sold 1,321 shares of the business’s stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total value of $104,874.19. Following the sale, the chief financial officer now owns 8,600 shares in the company, valued at approximately $682,754. The trade was a 13.32 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last ninety days, insiders have sold 2,930 shares of company stock valued at $217,170. 15.70% of the stock is currently owned by corporate insiders.

Moderna Stock Down 7.3 %

Shares of MRNA stock opened at $36.85 on Friday. The stock has a market cap of $14.18 billion, a P/E ratio of -6.33 and a beta of 1.69. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20. The stock has a fifty day moving average price of $59.28 and a 200 day moving average price of $97.40. Moderna, Inc. has a one year low of $35.80 and a one year high of $170.47.

Moderna (NASDAQ:MRNA) last issued its earnings results on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of ($1.89) by $1.92. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The business had revenue of $1.90 billion for the quarter, compared to analyst estimates of $1.25 billion. During the same period in the previous year, the business earned ($1.39) EPS. The firm’s revenue was up 3.8% on a year-over-year basis. Analysts predict that Moderna, Inc. will post -9.43 earnings per share for the current year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.